Rural Health
Resources by Topic: Pharmacy and prescription drugs
Trends in Opioid Prescribing by Oncologists for Medicare Beneficiaries from 2014 to 2022
Examines trends in opioid prescribing among oncologists before and after the FDA's 2018 Risk Evaluation and Mitigation Strategy for opioids revision, utilizing 2014-2022 Medicare Part D Prescriber Public Use Files data. Breaks down data by opioid type, oncologist subspecialty, geographic region, and rurality.
Author(s): Shaimaa Elshafie, Lorenzo Villa Zapata
Citation: Journal of Managed Care & Specialty Pharmacy, 31(10), 991-996
Date: 10/2025
view details
Examines trends in opioid prescribing among oncologists before and after the FDA's 2018 Risk Evaluation and Mitigation Strategy for opioids revision, utilizing 2014-2022 Medicare Part D Prescriber Public Use Files data. Breaks down data by opioid type, oncologist subspecialty, geographic region, and rurality.
Author(s): Shaimaa Elshafie, Lorenzo Villa Zapata
Citation: Journal of Managed Care & Specialty Pharmacy, 31(10), 991-996
Date: 10/2025
view details
Drone-Based Medication Delivery for Rural, Flood-Prone Coastal Communities
Discusses access to essential medical services and healthcare for rural communities in Virginia's flood-prone Eastern Shore. Utilizes geospatial data to examine the impact of drone-based medication delivery to overcome transportation barriers in these communities.
Author(s): Yin-Hsuen Chen, Amro M. El-Adle, Kevin J. O'Brien, Taylor Wentworth, Heather G. Richter
Citation: PLoS One, 20(10), e0333696
Date: 10/2025
view details
Discusses access to essential medical services and healthcare for rural communities in Virginia's flood-prone Eastern Shore. Utilizes geospatial data to examine the impact of drone-based medication delivery to overcome transportation barriers in these communities.
Author(s): Yin-Hsuen Chen, Amro M. El-Adle, Kevin J. O'Brien, Taylor Wentworth, Heather G. Richter
Citation: PLoS One, 20(10), e0333696
Date: 10/2025
view details
Inequity, Workload, and External Factors: A Descriptive Study on High-Intensity Statin Prescriptions for Patients with Clinical Cardiovascular Disease and at High Risk for Cardiovascular Disease
Examines adherence to guidelines related to statin prescriptions to treat atherosclerotic cardiovascular disease (ASCVD). Utilizes medical chart data from 20,923 ASCVD patients according to statin prescribing rates and patient demographics, including rural versus urban residence.
Author(s): Liberty Nguyen, Ethlyn Voorhies, Christy Jesme, et al.
Citation: BMC Cardiovascular Disorders, 25, 718
Date: 10/2025
view details
Examines adherence to guidelines related to statin prescriptions to treat atherosclerotic cardiovascular disease (ASCVD). Utilizes medical chart data from 20,923 ASCVD patients according to statin prescribing rates and patient demographics, including rural versus urban residence.
Author(s): Liberty Nguyen, Ethlyn Voorhies, Christy Jesme, et al.
Citation: BMC Cardiovascular Disorders, 25, 718
Date: 10/2025
view details
Estimating Emergency Department Utilization of Select Drugs during Extreme Heat Events
Examines excess emergency department (ED) visits and drug utilization surges for heat-related illness. Utilizes medical claims data to analyze heatwave related illnesses and provides modeling that predicts associated ED visits and drug utilization surges. Includes a county-level U.S. map showing days of extreme heat each year and discusses the impact on rural areas.
Author(s): Daniel McGeeney, Shruti Rathnavel, Emily McAden, Clifton Dassuncao, Aylin Sertkaya
Date: 09/2025
Sponsoring organizations: Eastern Research Group, Inc., HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Examines excess emergency department (ED) visits and drug utilization surges for heat-related illness. Utilizes medical claims data to analyze heatwave related illnesses and provides modeling that predicts associated ED visits and drug utilization surges. Includes a county-level U.S. map showing days of extreme heat each year and discusses the impact on rural areas.
Author(s): Daniel McGeeney, Shruti Rathnavel, Emily McAden, Clifton Dassuncao, Aylin Sertkaya
Date: 09/2025
Sponsoring organizations: Eastern Research Group, Inc., HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Diabetes in Pennsylvania: Prevention and Maintenance Programs
Present data and describes government and non-government programs working to help people prevent and manage diabetes in Pennsylvania. Includes information about possible new treatments and summaries of other new research on diabetes including the effects of social determinants of health. Mentions special needs of rural and underserved populations.
Author(s): Allison Kobzowicz, Lydia K. Ring, Wendy L. Baker
Date: 09/2025
Sponsoring organization: Joint State Government Commission, General Assembly of the Commonwealth of Pennsylvania
view details
Present data and describes government and non-government programs working to help people prevent and manage diabetes in Pennsylvania. Includes information about possible new treatments and summaries of other new research on diabetes including the effects of social determinants of health. Mentions special needs of rural and underserved populations.
Author(s): Allison Kobzowicz, Lydia K. Ring, Wendy L. Baker
Date: 09/2025
Sponsoring organization: Joint State Government Commission, General Assembly of the Commonwealth of Pennsylvania
view details
Rural Providers' Attitudes Toward Integrating Harm Reduction Strategies and PrEP Prescribing into Rural Primary Care Settings in the US. Southeast and Midwest
Examines the perceptions of providers working in rural primary care settings toward buprenorphine, methadone, comprehensive harm reduction, and PrEP prescriptions. Analyzes 409 providers treating either a person with opioid use disorder or a person with HIV and provides data breakdowns on PrEP prescriptions, medications for opioid use disorder (MOUD), and perceptions toward harm reduction integration.
Author(s): Phillip L. Marotta, Miryam Biaid, Robert Heimer, et al.
Citation: Addiction Science & Clinical Practice, 20, 73
Date: 09/2025
view details
Examines the perceptions of providers working in rural primary care settings toward buprenorphine, methadone, comprehensive harm reduction, and PrEP prescriptions. Analyzes 409 providers treating either a person with opioid use disorder or a person with HIV and provides data breakdowns on PrEP prescriptions, medications for opioid use disorder (MOUD), and perceptions toward harm reduction integration.
Author(s): Phillip L. Marotta, Miryam Biaid, Robert Heimer, et al.
Citation: Addiction Science & Clinical Practice, 20, 73
Date: 09/2025
view details
Medications for Opioid Use Disorder among Adults Who Had an Opioid Use Disorder
Offers data on adults receiving medications for opioid use disorder between 2022 and 2024 by age, sex, region, and metropolitan county status.
Date: 09/2025
Sponsoring organization: Substance Abuse and Mental Health Services Administration
view details
Offers data on adults receiving medications for opioid use disorder between 2022 and 2024 by age, sex, region, and metropolitan county status.
Date: 09/2025
Sponsoring organization: Substance Abuse and Mental Health Services Administration
view details
The 340B Drug Discount Program: Litigation Topics and Trends
Provides an overview of the 340B Drug Discount Program. Discusses litigation surrounding the 340B program, including lawsuits against 340B-covered entities over their use of contract pharmacies to distribute 340B drugs to patients and lawsuits against states that have enacted laws to protect contract pharmacies and covered entities inside their state. Describes courts' interpretation of the 340B statute. Offers considerations for the 119th Congress in light of the litigation and describes several legislative changes that Congress could make to the program if it chose to do so.
Date: 09/2025
Sponsoring organization: Congressional Research Service
view details
Provides an overview of the 340B Drug Discount Program. Discusses litigation surrounding the 340B program, including lawsuits against 340B-covered entities over their use of contract pharmacies to distribute 340B drugs to patients and lawsuits against states that have enacted laws to protect contract pharmacies and covered entities inside their state. Describes courts' interpretation of the 340B statute. Offers considerations for the 119th Congress in light of the litigation and describes several legislative changes that Congress could make to the program if it chose to do so.
Date: 09/2025
Sponsoring organization: Congressional Research Service
view details
Growth in the 340B Drug Pricing Program
Explores trends in drug purchases through the 340B program between 2010-2021. Discusses drugs purchased through the Prime Vendor Program, factors contributing to growth in the 340B program, and effects of the 340B program on the federal budget. Includes information on the growth of 340B Program participation by hospitals in Medicaid expansion and non-expansion states by Critical Access Hospital designation.
Additional links: Data Underlying Figures
Date: 09/2025
Sponsoring organization: Congressional Budget Office
view details
Explores trends in drug purchases through the 340B program between 2010-2021. Discusses drugs purchased through the Prime Vendor Program, factors contributing to growth in the 340B program, and effects of the 340B program on the federal budget. Includes information on the growth of 340B Program participation by hospitals in Medicaid expansion and non-expansion states by Critical Access Hospital designation.
Additional links: Data Underlying Figures
Date: 09/2025
Sponsoring organization: Congressional Budget Office
view details
Pharmacy Barriers to Receiving Buprenorphine Among Patients Undergoing Telemedicine Addiction Treatment
Presents a study exploring pharmacy-level barriers experienced by patients with opioid use disorder who are receiving treatment via telemedicine. Discusses barriers that lead to missed doses or inaccessible prescriptions. Breaks down data by health and demographic characteristics, such as age, education, and insurance type, among others, and whether the patient lived in a rural or nonrural area.
Author(s): Lauren E. Hendy, Lucas G. Hill, Amanda Olguin, et al.
Citation: JAMA Network Open, 8(8), e2527418
Date: 08/2025
view details
Presents a study exploring pharmacy-level barriers experienced by patients with opioid use disorder who are receiving treatment via telemedicine. Discusses barriers that lead to missed doses or inaccessible prescriptions. Breaks down data by health and demographic characteristics, such as age, education, and insurance type, among others, and whether the patient lived in a rural or nonrural area.
Author(s): Lauren E. Hendy, Lucas G. Hill, Amanda Olguin, et al.
Citation: JAMA Network Open, 8(8), e2527418
Date: 08/2025
view details